Director Saira Ramasastry will not stand for re-election at Sangamo's 2022 annual meeting

SANGAMO THERAPEUTICS, INC

Ms. Ramasastry notified the Board on March 28, 2022, of her decision not to stand for re-election.
She has served as a director since June 2012 and is the longest tenured Board member.
Her decision is not due to any disagreement with the Company on operations, policies, or practices.
The annual meeting is scheduled for May 24, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Saira Ramasastry

Director

SGMO · SANGAMO THERAPEUTICS, INC

Effective: 2022-05-24
Filed: April 1, 2022, 7:59 PM ET

On March 28, 2022, Saira Ramasastry, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”) since June 2012, notified the Company of her decision not to stand for re-election at the Company’s annual meeting of stockholders to be held on May 24, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Saira Ramasastry departed as Director at SANGAMO THERAPEUTICS, INC.

Action: notified decision not to stand for re-election
Role: Director

Exact text from the filing

On March 28, 2022, Saira Ramasastry, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”) since June 2012, notified the Company of her decision not to stand for re-election at the Company’s annual meeting of stockholders to be held on May 24, 2022.

View on SEC.gov

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-22-008157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.